Pasithea Therapeutics (KTTA) Equity Ratio (2021 - 2024)
Historic Equity Ratio for Pasithea Therapeutics (KTTA) over the last 4 years, with Q3 2024 value amounting to 0.96.
- Pasithea Therapeutics' Equity Ratio rose 327.21% to 0.96 in Q3 2024 from the same period last year, while for Sep 2024 it was 0.96, marking a year-over-year increase of 327.21%. This contributed to the annual value of 0.9 for FY2023, which is 475.5% down from last year.
- According to the latest figures from Q3 2024, Pasithea Therapeutics' Equity Ratio is 0.96, which was up 327.21% from 0.92 recorded in Q2 2024.
- Over the past 5 years, Pasithea Therapeutics' Equity Ratio peaked at 0.98 during Q1 2022, and registered a low of 0.78 during Q3 2021.
- Moreover, its 4-year median value for Equity Ratio was 0.93 (2023), whereas its average is 0.92.
- As far as peak fluctuations go, Pasithea Therapeutics' Equity Ratio soared by 2046.33% in 2022, and later tumbled by 486.98% in 2023.
- Over the past 4 years, Pasithea Therapeutics' Equity Ratio (Quarter) stood at 0.96 in 2021, then dropped by 2.46% to 0.94 in 2022, then fell by 4.75% to 0.9 in 2023, then increased by 6.68% to 0.96 in 2024.
- Its Equity Ratio stands at 0.96 for Q3 2024, versus 0.92 for Q2 2024 and 0.89 for Q1 2024.